Clinical Trial Results:
Is there an interest in repeating the vaginal administration of dinoprostone ( Propess® ) , to promote cervical ripening of pregnant women at term?
|
Summary
|
|
EudraCT number |
2016-000147-13 |
Trial protocol |
FR |
Global end of trial date |
23 Apr 2022
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Nov 2026
|
First version publication date |
08 Nov 2026
|
Other versions |
|
Summary report(s) |
Journal article |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
|
Trial identification
|
|||
Sponsor protocol code |
I15014
|
||
|
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02888041 | ||
WHO universal trial number (UTN) |
- | ||
|
Sponsors
|
|||
Sponsor organisation name |
CHU de Limoges
|
||
Sponsor organisation address |
2 avenue Martin Luther King, Limoges, France, 87042
|
||
Public contact |
Direction Research and Innovation, CHU de LIMOGES, +33 555056349, drc@chu-limoges.fr
|
||
Scientific contact |
Direction Research and Innovation, CHU de LIMOGES, +33 555056349, drc@chu-limoges.fr
|
||
Sponsor organisation name |
CHU de Limoges
|
||
Sponsor organisation address |
2 avenue martin luther king, limoges, France, 87042
|
||
Public contact |
Renaud MARTIN, Limoges university hospital, +55 555055555, dri@chu-limoges.fr
|
||
Scientific contact |
Renaud MARTIN, Limoges university hospital, +33 555055555, dri@chu-limoges.fr
|
||
|
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
|
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
20 Feb 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
23 Apr 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
23 Apr 2022
|
||
Was the trial ended prematurely? |
Yes
|
||
|
General information about the trial
|
|||
Main objective of the trial |
Demonstrate, if cervical ripening failure by a first Propess®, the laying of a second Propess® (followed if necessary by oxytocin (Syntocinon®)) increases the rate of births vaginally by compared to the direct injection of oxytocin (Syntocinon®).
|
||
Protection of trial subjects |
Condition de prise en charge standard pour ce genre de situation
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
04 Jul 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
|
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
France: 160
|
||
Worldwide total number of subjects |
160
|
||
EEA total number of subjects |
160
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
160
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
||
|
||||||||||
|
Recruitment
|
||||||||||
Recruitment details |
recrutement entre décembre 2016 et avril 2022 au niveau national | |||||||||
|
Pre-assignment
|
||||||||||
Screening details |
Les patientes sont informées du protocole soit lors de la consultation où le déclenchement est programmé, ou au plus tard, lorsque le déclenchement est débuté (hospitalisation). Les patientes bénéficient donc d’un délai de réflexion de 24 heures minimum. | |||||||||
|
Period 1
|
||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Not blinded | |||||||||
Blinding implementation details |
Not applicable
|
|||||||||
|
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
|
Arm title
|
Propess | |||||||||
Arm description |
In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient. | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
Dinoprostone
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Vaginal delivery system
|
|||||||||
Routes of administration |
Vaginal use
|
|||||||||
Dosage and administration details |
20 mg milligram(s) total sur une période max de 48H
|
|||||||||
|
Arm title
|
Syntocinon | |||||||||
Arm description |
In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient. | |||||||||
Arm type |
Active comparator | |||||||||
Investigational medicinal product name |
Oxytocin
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Injection
|
|||||||||
Routes of administration |
Intravenous use
|
|||||||||
Dosage and administration details |
10 IU international unit(s) max
|
|||||||||
|
||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
|
End points reporting groups
|
|||
Reporting group title |
Propess
|
||
Reporting group description |
In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient. | ||
Reporting group title |
Syntocinon
|
||
Reporting group description |
In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient. | ||
|
||||||||||
End point title |
Rate of deliveries vaginally | |||||||||
End point description |
||||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
At delivery
|
|||||||||
|
||||||||||
Statistical analysis title |
Vaginal delivery rate — between-group comparison | |||||||||
Comparison groups |
Propess v Syntocinon
|
|||||||||
Number of subjects included in analysis |
160
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
= 0.715 | |||||||||
Method |
Chi-squared | |||||||||
Parameter type |
Relative risk | |||||||||
Point estimate |
1.03
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
0.86 | |||||||||
upper limit |
1.24 | |||||||||
Variability estimate |
Standard deviation
|
|||||||||
|
||||||||||
End point title |
Failure of induction of labor | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At delivery
|
|||||||||
|
||||||||||
| No statistical analyses for this end point | ||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From the first patient in to last patient out
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
25.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Propess
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Syntocinon
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||
Substantial protocol amendments (globally) |
||||||||||
| Were there any global substantial amendments to the protocol? Yes | ||||||||||
Date |
Amendment |
|||||||||
14 Nov 2019 |
Ajout critère de non inclusion |
|||||||||
Interruptions (globally) |
||||||||||
| Were there any global interruptions to the trial? Yes | ||||||||||
|
||||||||||
Limitations and caveats |
||||||||||
| Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | ||||||||||
| None reported | ||||||||||
Online references |
||||||||||
| http://www.ncbi.nlm.nih.gov/pubmed/39343101 |
||||||||||